NICE recommends palbociclib and ribociclib for breast cancer

NICE recommends palbociclib and ribociclib for breast cancer PharmacoEconomics & Outcomes News 792, p35 - 2 Dec 2017 NICE recommends palbociclib and ribociclib for breast cancer In draft guidance, the UK National Institute for Health and Care Excellence (NICE) recommends palbociclib (Ibrance) and ribociclib (Kisqali) for the treatment of locally advanced, hormone receptor positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, or secondary breast cancer. Both drugs were recommended for routine access within the National Health Service after their drug manufacturers (Pfizer and Novartis, respectively) agreed to reduce their prices. The drugs appear to increase progression-free survival by approximately 10 months, and may reduce chemotherapy requirements. They are both administered orally, once daily, in combination with an aromatase inhibitor. "The committee heard that by postponing disease progression, palbociclib and ribociclib may reduce the number of people who are exposed to the often unpleasant side effects of chemotherapy, and delay the need for its use in others," said Professor Carole Longson, director of the centre for health technology evaluation at NICE. "We are pleased therefore that the companies have been able to agree reductions to the price of palbociclib and ribociclib to allow them to be made routinely available to people with this type of breast cancer," she added. NICE. Breast cancer patients to have routine access to two life extending drugs after new deal, say NICE in draft guidance Internet Document : 16 Nov 2017. Available from: URL: to-have-routine-access-to-two-life-extending-drugs-after-new-deal-say-nice-in-draft- guidance 803283868 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792 PharmacoEconomics & Outcomes News Springer Journals

NICE recommends palbociclib and ribociclib for breast cancer

1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial